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Summary
Objective: To verify the clinical alterations and, in particular, hepatic laboratory alterations in patients in each of the 
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to a tertiary hospital with the diagnosis of heart failure were researched by means of a cross sectional study. The patients 
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of any etiology were excluded. 
Results: Analysis of the mean transaminase values revealed a significant increase only for the Class IV patients. On the 
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Introduction
Recent studies have classified liver complications associated 
with heart failure in three general groups: a) congestive hepatic 
fibrosis and cardiac cirrhosis; b) cardiogenic ischemic hepatitis; 
c) moderate liver function test alterations in congestive heart 
failure1.
Cardiac cirrhosis and congestive hepatic fibrosis are 
characterized by collagen deposits in the lobules with and 
without the formation of regeneration nodules, respectively. 
Both represent reactions ranging from hepatic stroma to 
situations of increased venous pressure, hypoxia or hepatocyte 
necrosis. Nevertheless, while cardiac cirrhosis today is clinically 
defined by the triad of right sided heart failure in association 
with hepatomegaly, ascites with a high protein concentration 
and elevated serum-ascites-albumin gradient, congestive 
hepatic fibrosis remains clinically silent.
Cardiogenic ischemic hepatitis is characterized by the 
dramatic transaminase serum increase after an acute and 
serious drop in cardiac output. It usually occurs within 2 to 
24 hours after the causal phenomenon. The initial symptoms 
are usually weakness and apathy, but occasionally it can cause 
mental confusion, jaundice, oliguria, flapping and hepatic 
coma. Laboratory alterations in addition to the transaminase 
serum increase include elevated LDH and bilirubin serum levels 
and an increased prothrombin time. For patients who survive 
the cardiogenic ischemic hepatitis episode, liver function test 
abnormalities peak within one to three days and return to 
normal within five to ten days after the onset of symptoms1.
Most studies that include the clinical presentation of 
patients with cardiogenic ischemic hepatitis list cardiogenic 
shock as the causal factor for the drop in cardiac output2-4.
Researchers, over the past few years, have been attempting 
to determine the relationship between this entity and the 
hepatic alterations it causes. This research has led to a better 
understanding of how the maximum degree of heart failure 
– cardiogenic shock affects the liver. 
Nevertheless, very little is known in regard to moderate 
alterations in liver function tests resulting from lesser degrees 
of congestive heart failure, and even less is known about 
the clinical manifestations of liver dysfunction in these 
circumstances. It is known that the enzyme abnormalities 
improve with heart failure compensation and that one third 
of the patients present moderate jaundice1.
The objective of this study was to establish a profile of both 
the clinical and laboratory alterations that the different degrees 
of congestive heart failure cause in the patient. Attention was 
focused on the liver and therefore major consideration was 
given to the liver function tests and symptoms that indicate 
liver damage or dysfunction.
Methods
The clinical and laboratory data of 50 individuals diagnosed 
with any degree of heart failure, including cardiogenic shock, 
were researched by means of a cross sectional study.
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Comparisons of the patients’ laboratory data for the 
different heart failure classes were conducted using the 
Student’s t-test with a significance level of p < 0.05.
The heart failure classes were obtained from the medical 
histories in accordance with the criteria prepared by the New 
York Heart Association (NYHA): class I (patients with heart 
disease however asymptomatic during ordinary activities), class 
II (slight limitation of physical activity; ordinary activity results 
in fatigue, palpitation, dyspnea or chest pain), class III (marked 
limitation of physical activity; less than ordinary activity causes 
symptoms) and class IV (symptoms at rest).
For the patients who had an echocardiogram, the ventricular 
ejection fraction (EF) values (Teichholtz method) were obtained 
for later correlation with the heart failure level.
Patients with a history of any type of hepatitis, 
noncardiogenic shock, hepatic tumor, hepatic trauma, 
alcoholism, noncardiogenic cirrhosis of the liver or other liver 
or bile duct diseases were not analyzed. Patients with any 
type of bone disease as well as neoplasias or metastases in 
any location were excluded due to the possibility of increased 
alkaline phosphatase. Patients who were admitted for acute 
myocardial infarction were also excluded due to the possibility 
of increased aspartate aminotransferase serum levels.
Comparisons of the patients’ laboratory data for the 
different heart failure classes were conducted using the 
Student’s t-test with a significance level of p < 0.05.
Results
From the 337 patients, the medical charts of 175 (51.93%) 
were analyzed. From these, 125 (71.43%) had one of the 
exclusion factors and the remaining 50 (28.57%) fulfilled the 
requirements for the study.
In relation to gender, 32 were female (64%). In regard 
to skin color, 33 (66%) were white, 10 (20%) mulattos, and 
seven (14%) negro. In relation to age groups, there were no 
patients between the ages of zero and ten years; one patient 
(2%) between 11 and 20 years ; one patient between 21 and 
30 years; 2 patients (4%) between 31 and 40 years; 5 patients 
(10%) between 41 and 50 years; 9 (18%) between 51 and 60 
years; 17 (34%) between 61 and 70 years; 12 (24%) between 
71 and 80 years and 3 (6%) older than 81 years.
In regard to causal diagnoses of congestive heart failure, the 
main cause was systemic hypertension in 31 patients (62%), 
followed by acute myocardial infarction, affecting 15 (30%), 
and Chagas disease in 13 (26%). Six had valvular heart disease 
(12%) and three had stable angina (6%). Systemic sclerosis, 
atrial fibrillation, hyperthyroidism, hypothyroidism and obesity 
were each presented by one patient.
From the 50 patients in the study, six (12%) had class I 
heart failure, 10 (20%) class II, 18 (36%) class III, and 16 
(32%) class IV.
During the decompensation phase, 47 patients (94%) 
presented dyspnea, 25 (50%) edema in the lower extremities, 
15 (30%) nocturnal paroxysmal dyspnea, 13 (26%) 
orthopnea, 7 (14%) fatigue, and 4 (8%) anasarca. Chest 
pain, tachycardia, nocturia, oliguria, loss of appetite and 
lethargy were each presented by two patients. One patient 
The study population was chosen from a sample of 337 
patients admitted to a tertiary hospital, by tracking the 
International Classification of Diseases code for the diagnosis 
of heart failure (CID I500) and data collected from the patients’ 
medical charts.
Data analyzed from each medical chart included: a) clinical 
signs of liver failure such as hepatic encephalopathy, jaundice, 
coagulopathy, hypoglycemia, metabolic acidosis, pruritus, 
ascites and telangiectasias; b) laboratory signs of hepatic 
cellular lesion, liver dysfunction and cholestasis (aspartate 
aminotransferase [AST], alanine aminotransferase [ALT], gamma-
glutamyl transpeptidase [GGT], alkaline phosphatase [AP], direct 
bilirubin [DB], indirect bilirubin [IB] and total bilirubin [TB], 
albumin, coagulation factors and coagulogram [R and RNI]). The 
laboratory data were collected within a maximum timeframe 
of four days after decompensation, a period in which possible 
alterations are usually observed. The reference numbers used 
for the research are as follows (Table1):
The heart failure classes were obtained from the medical 
histories in accordance with the criteria prepared by the New 
York Heart Association (NYHA): class I (patients with heart 
disease however asymptomatic during ordinary activities), class 
II (slight limitation of physical activity; ordinary activity results 
in fatigue, palpitation, dyspnea or chest pain), class III (marked 
limitation of physical activity; less than ordinary activity causes 
symptoms) and class IV (symptoms at rest).
For the patients who had an echocardiogram, the ventricular 
ejection fraction (EF) values (Teichholtz method) were obtained 
for later correlation with the heart failure level.
Patients with a history of any type of hepatitis, 
noncardiogenic shock, hepatic tumor, hepatic trauma, 
alcoholism, noncardiogenic cirrhosis of the liver or other liver 
or bile duct diseases were not analyzed. Patients with any 
type of bone disease as well as neoplasias or metastases in 
any location were excluded due to the possibility of increased 
alkaline phosphatase. Patients who were admitted for acute 
myocardial infarction were also excluded due to the possibility 
of increased aspartate aminotransferase serum levels.
Table 1 – Reference laboratory values adopted upon admission to the 
hospital
AST Male – up to 37 U/lFemale – up to 31 U/l
ALT Male – up to 40 U/lFemale – up to 30 U/l
AP Male – 40 to 129 U/lFemale – 35 to 104 U/l
GGT Male – up to 269 U/lFemale – up to 239 U/l
DB Up to 0.2 mg/dl
IB Up to 0.8 mg/dl
TB Up to 1.0 mg/dl
R Up to 1.3
RNI Up to 1.25
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presented abdominal pain and nausea. Four patients (8%) 
suffered from cardiogenic shock. At the conclusion of the 
hospital admission timeframe chosen for analysis purposes 
there had been seven deaths (14%).
The results of the laboratory data are as follows (Table 2):
and the standard deviation 5.65. The lowest value was 8 U/L 
and the highest 23 U/L. The class II patients had a median of 18 
U/L, and the standard deviation was 14.29. The lowest value 
was 9 U/L and the highest 56 U/L. Among the class III patients 
the median was 19 U/L and the standard deviation 22.09. The 
Bivariate analysis was used for the CHF class and hepatic 
enzymes, revealing the following results. 
AST - Among the six patients with class I heart failure, the 
lowest value was 13 U/L and the highest 30 U/L. The standard 
deviation was 6.85 and the median 20.5 U/L. Among the 10 
class II patients, the standard deviation was 6. The lowest value 
was 11 U/L and the highest 30 U/L. The median was 20.5 
U/L. The highest AST value among the patients with class III 
congestive heart failure was 158 U/L and the lowest 13 U/L. 
The standard deviation was 32.67 and the median was 20.5 
U/L. Among the 16 patients with class IV HF the standard 
deviation was 28.05 and the median 54. The lowest value 
was 7 U/L and the highest 126 U/L (graphic 1). Analysis of 
the mean AST values using the Student’s t-test was statistically 
significant only when the class IV mean value was compared 
to the other averages.
ALT - Among the patients in class I, the median was 16 U/L 
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Graphic 1 – Mean AST Values by CHF Class.
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lowest value was 3 U/L and the highest 100 U/L. Among the 
class IV patients the lowest value was 2 U/L and the highest 
264 U/L. The median was 61 U/L and the standard deviation 
was 63.80 (graphic 2). Analysis of the mean ALT values using 
the Student’s t-test was statistically significant only when the 
class IV mean value was compared to the other averages.
AP - Among the class I patients the median was 193 U/L 
and the standard deviation was 23.89. The lowest value was 
149 U/L and the highest 202 U/L. The class II patients had a 
median of 216.5 U/L, and the standard deviation was 58.53. 
The lowest value was 139 U/L and the highest 344 U/L. Among 
the class III patients the median was 195 U/L and the standard 
deviation 127.90. The lowest value was 124 U/L and the 
highest was 572 U/L. Among the class IV patients the lowest 
value was 171 U/L and the highest was 461 U/L. The median 
was 293.5 U/L and the standard deviation was 109.87 (graphic 
3). The analysis of the mean AP values using the Student’s t-
test was statistically significant only for comparisons between 
Graphic 2 – Mean ALT Values by CHF Class.
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Table 2 – Individual evaluation of the study variables
Patients Lowest value +LJKHVWYDOXH Mean Median Standarddeviation
AST (U/l) 50 7 158 34.08 24.5 28.18
ALT (U/l) 50 2 264 36.14 19 44.07
AP (U/l) 33 124 572 249.75 205 101.26
GGT (U/l) 30 12 883 119 75.5 162
DB (mg/dl) 14 0.1 2.3 0.55 0.4 0.58
IB (mg/dl) 14 0.2 3.0 0.67 0.4 0.72
TB (mg/dl) 14 0.4 5.3 1.22 0.7 1.29
R 35 0.85 1.64 1.15 1.12 0.18
RNI 35 0.95 2.72 1.29 1.2 0.33
Echo (%) 21 17.30 50.80 34.48 35.25 9.79
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in the genesis of most heart failure cases such as acute 
myocardial infarction and hypertension that tend to appear 
in older individuals.
Contrary to the adult population, whose CHF prevalence 
is relatively consistent throughout the world6, the number 
of children affected by this condition varies considerably 
according to the region being studied7. In the present project, 
only one of the 50 patients studied (or in other words, 2%) 
was in the pediatric age group.
As mentioned earlier, among the 50 patients selected for 
the study there were 18 males and 32 females. Nevertheless, 
this should not be considered as a true proportion of heart 
failure cases between the two genders since the selection was 
biased and the exclusion factors predominated in the male 
gender. In the group of 175 patients that were considered for 
the study, 91 (52%) were men and 84 (48%) were women. 
From the 125 patients that did not participate in the study 
due to some exclusion factor, 74 (59.2%) were males and 51 
(40.8%) were females.
The best manner found to establish gender distribution for 
this paper was the study of the initial group of 337 patients. 
From these, 186 (55.20%) were male. The higher incidence 
of congestive heart failure and deaths among the male 
gender agrees with documented data in medical literature. 
Most studies indicate that the disease is found less often in 
women and when it is found it is not as severe8.9 due to the 
better cardiac remodeling characteristic of this gender. The 
underlying reasons responsible for this reality are not yet firmly 
established, nevertheless, it is believed that female hormone 
differences and myocardiocytes with greater resistance to 
apoptosis are contributing factors.
In regard to hormonal differences, estrogen seems to play 
an essential role. Many of its effects on cardiovascular system 
cells are known and considered beneficial. It is estimated that 
close to 5% of the proteins produced by the myocardiocytes 
are regulated by estrogen including the endotelina-1 receptor 
expression10.
As expected, the two most common CHF etiologies found 
in this study were systemic hypertension and acute myocardial 
infarction. However, the importance of these two diseases 
conflicted with the findings of various studies that indicate 
coronary artery disease as the most common cause of heart 
failure11,12. Valvular heart disease, that in the past was the main 
etiology, is becoming less prevalent. In this study, it was the 
fourth main etiology, presented by 12% of the patients.
At this time it should be emphasized, that the 16 patients 
included in the study with New York Heart Association 
functional classes I and II were not admitted to the hospital 
for congestive heart failure. The reasons were very diverse 
– decompensation of chronic kidney failure was the most 
common, cellulite in the lower limbs, atrial fibrillation, etc. 
– however none of them were comorbidities considered in 
the study exclusion criteria.
The transaminase results revealed a significant increase 
only in the class IV heart failure patients. Nevertheless, it was 
a slight increase and was not consistent with the ischemic 
hepatitis profile, where values 10 to 20 times higher than the 
normal limits are expected1. These data demonstrate that 
classes I and III and between classes I and IV. 
GGT - Among the class I patients the median was 24 U/L 
and the standard deviation was 12.83. The lowest value was 12 
U/L and the highest 40 U/L. The class II patients had a median 
of 56 U/L and standard deviation of 70.93. The lowest value 
was 22 U/L and the highest 218 U/L. The median among the 
class III patients was 77 U/L and the standard deviation was 
252.50. The lowest value was 18 U/L and the highest was 883 
U/L. Among the class IV patients the lowest value was 18 U/L 
and the highest was 334 U/L. The median was 116 U/L and 
the standard deviation was 88.58 (graphic 4). Analysis of the 
mean GGT values using the Student’s t-test was statistically 
significant only when the class I averages were compared with 
the other classes.
Graphic 4 – Mean GGT Values by CHF Class.
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Analysis of the mean GGT values using the Student’s t-test 
is represented by the p-value shown in each of the following 
graphics.
CHF class versus deaths - There were no deaths among the 
class I and II patients. Among the 18 class III patients there 
were two deaths (11.11%) and among the class IV patients 
there were five deaths (31.25%).
Discussion
In regard to age groups, the results obtained agreed with 
those in medical literature, showing that the incidence of 
congestive heart failure increases with age. It is known that 
the prevalence doubles with every decade of life and that it is 
found in roughly 40% of the people above age 705.
One possible explanation for this age distribution can be 
found by analyzing the incidence rates of the factors involved 
Graphic 3 – Mean AP Values by CHF Class.
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echocardiogram with hepatic laboratory alterations14 this 
cholestasis profile was also present and progressed in 
accordance with the degree of regurgitation. Furthermore, 
increased bilirubin levels and hepatic synthesis function 
abnormalities were also recorded as indicated by the 
hypoalbuminemia found. These results were not seen in the 
present study since the bilirubin and albumin serum levels 
close to the date of the decompensation episode, were not 
recorded on most of the patients’ medical charts.
Alkaline phosphatase and GGT are located in the 
bile duct and are elevated in situations where the biliary 
canaliculi suffer some type of damage. Elevated levels of 
these enzymes in congestive heart failure patients indicates 
that there are other mechanisms responsible for liver 
failure in CHF in addition to the traditional mechanisms 
that associate ischemia and congestion with hepatocellular 
lesions (elevated AST and ALT levels). One of these models15
is based on increased mechanical pressure within the 
hepatic sinusoids that is associated with sinusoid endothelial 
cell lesions and consequent direct pressure transmission 
to the hepatocytes and their tight junctions. With this 
increased pressure, the tight junctions, that are responsible 
to separated the extravascular matrix from the biliary 
canaliculi, would rupture causing a fistula between these 
two compartments. These alterations have been proven by 
microscopic assessment of rats submitted to hepatic venous 
return obstructions. Similar alterations have been reported 
in humans with extrahepatic cholestasis.
Nevertheless, the conflicting opinions and studies in medical 
literature demonstrate that the profile of hepatic laboratory 
alterations in heart failure is not yet established. Some consider 
the predominant transaminase increase to be typical while 
others defend the cholestatic or mixed model13-15. Still others, 
do not believe that there is a specific pattern. The understanding 
of these alterations is of utmost importance in order to avoid 
unnecessary hepatic investigations in heart failure patients. 
Patients that exhibit a moderate increase of AP and GGT, for 
example, could receive intensive heart failure therapy before 
other liver disease examinations have been performed so as 
to avoid delaying the diagnosis and submitting the patients to 
invasive procedures such as liver biopsies.
serious circulation problems such as shock are not necessary 
for the development of hepatic cellular lesions, even though 
they would be much more evident in this situation. They 
also reveal that congestion and diminished hepatic perfusion 
in class I, II and III heart failure patients are not sufficient to 
cause hepatocyte lesions.
These results are compatible with those obtained in a 
study that sought to relate cardiac output and liver function 
abnormalities13. The patients were divided in three groups 
according to cardiac output. Significant increases of AST and 
ALT were only observed in the group with the worst output 
(less than or equal to 1.5 L/min/m2).
Analysis of the alkaline phosphatase and gamma glutamyl 
transpeptidase (GGT) results revealed a distinct profile in 
relation to the transaminases. Generally, the serum levels of 
these enzymes increased progressively with the more severe 
heart failure classes. Comparison of the averages of the 
class II, III and IV patients with those of the class I patients, 
confirmed that these increases were more significant in the 
more advanced classes. Only two situations did not follow this 
trend. Comparison of the mean alkaline phosphatase values 
between the class I and II patients, presented a p-value of 
0.07834. Even though this value is not statistically significant, 
it is very close and with a larger study group it could have 
been significant. The other situation is the drop in the mean 
gamma glutamyl transpeptidase value from class III to class 
IV instead of the expected increase. This can be explained by 
the discrepant and significantly elevated GGT value (883 U/L) 
of one class III patient that raised the average.
Based on these data it can be said that heart failure is 
characterized by a cholestatic profile of laboratory alterations 
with increased levels of alkaline phosphatase and GGT, and 
that the seriousness of the cholestasis correlates with the CHF 
class. Considering that alkaline phosphatase is produced by 
the hepatocytes and GGT by the bile duct epithelial cells, this 
could indicate that the hepatocytes and the bile duct epithelia 
are the main hepatopathy targets in these patients(14) as there 
is a certain degree of intrahepatic biliary obstruction even with 
the most moderate levels of heart failure.
In a prospective study to evaluate the relation between 
the degree of tricuspid regurgitation observed on an 
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